NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
According to recent industrial report, only several products from worldwide NMN manufacturers came close to meeting label claim and contain not enough NMN. Almost products performed better, having at least 88% of the label claim up to small overages. A lone 250 mg product was identified as BRL. In sum, ChromaDex said that 64% of the products tested contained less than 1% of the stated amount of the active ingredient. which should give consumers pause. While this is a limited snapshot of the vast NMN finished product landscape. it does provide a glimpse into the high variability of product quality that is available. The majority of the products may purchase online contain such a small amount of NMN that there would be no clinical benefits achieved from the dose. Another concern with these adulterated products is that the actual contents are not known and could pose a risk to the user the company said in a statement.
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
1.Raw material production process
Bioenzyme catalysis is a popular production method in the industry. It has a high threshold and several key catalytic enzymes are expensive, accounting for about 80% of the overall production process cost, but it is also the safest and most efficient production method. In the production of NMN by bioenzyme catalysis, the use of food-grade raw materials is an important part of the process to ensure product safety and to ensure that standards are followed.
2.High standard of production conditions
Production conditions refer to the standard of labor consumption required to complete the qualified products of the unit under certain production organization and production technology conditions. There are certifications issued by regulatory authorities, such as cGMP in the United States, TGA in Australia, GMP in Japan, etc.
3.High standard of product testing.
Product testing requires reliable test methods and reagents that are used throughout the production process. They are not only inspection standards for the final product, but also for the intermediate stages of control, including testing of active ingredients, testing of heavy metals such as lead, arsenic and mercury, and testing of pathogenic bacteria, microorganisms and processing by-products.
For NMN products, the commonly used method for active ingredient content testing is high performance liquid chromatography (HPLC), which is efficient, accurate and precise. For different manufacturers, the standards for testing reagents are different. Strict manufacturers will purchase high purity, analytically pure reagents from third party standards companies as controls.
4.Safety assessment
For relatively new raw materials such as NMN, it is not enough for consumers to judge the safety of the product on the side of the merchant alone. At this point, the third-party authoritative assessment report is particularly important.
Currently, there are two generic safety assessment reports, one is a toxicological assessment report and the other is a safety assessment report. In China, toxicological assessment reports usually account for the majority. However, there are still few NMN companies that can issue such reports
5.Storage and Packaging
NMNs are usually stored in sealed containers for up to 12 months. If it can be stored for 24 months with insignificant changes in purity, the stability of NMN is very reliable. Currently, the more common packaging materials are pet or hope, which are pharmaceutical packaging materials. They are non-toxic, odorless, lightweight, portable and effectively isolate air and moisture.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been backed up by rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often sold as functional food product rather than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of consumers. NMN should not be considered as a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors have been studied to discover the efficacy for diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction On January 9, 2024, the expert team of selection organizing committee from Deloitte visited BONTAC, and presented the trophy of “China Life Sciences & Healthcare Rising Star” to BONTAC on site. By virtue of its unique and innovative technology in the field of coenzymes, professional R&D team with rich experience, and excellent performance in the industry of biosynthesis, BONTAC has stood out from the crowd and won the award of "Deloitte China Life Sciences & Healthcare Rising Star". 2. 2023 Deloitte China Life Sciences & Healthcare Rising Star Since the launch of “Deloitte China Life Sciences & Healthcare Rising Star” campaign by the end of June 2023, extensive attention has been attracted by the Chinese medicine and health industry. Following verification by site visit of the enterprises, 50 enterprises with prominent comprehensive strength are finally determined to be eligible, which are subjected to rigorous review of multiple dimensions such as financial asset valuation, founding team, technical innovation, market prospect, industrial rank, etc. The awarded enterprises in this selection campaign encompass the advanced enterprise in the niche areas of life sciences and healthcare, who comprehensively display their multiple innovation achievements in the field of life sciences and healthcare. The “Deloitte China Life Sciences & Healthcare Rising Star” selection campaign is a key subproject of Deloitt on the selection project of high-tech and fast-growing enterprises, aiming to recognize and award the outstanding enterprises who take the lead in their niche areas of life sciences and healthcare and have great growth potential. 3. The candidate enterprises must meet the the following criteria: * Business headquartered within China Mainland, Hong Kong or Macao. * Own leading technology and viable business models. * Have extensive growth potential with a leading position in their niche segments. 4. Current situation on Chinese medicine and health industry The technical innovation and product quality in Chinese medicine and health industry have continuously improved, which is driven by healthcare reform policies, emerging technologies and capital markets. In China, independent innovation has penetrated into all tracks of the major health industry, which greatly promotes the research and development of domestically produced innovative medicines and medical technologies. Substantial promising innovative enterprises has emerged and gradually gained recognition in the global market, ranking among the first echelon of global technological innovation. 5. About BONTAC BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. BONTAC adheres to independent innovation, with more than 160 invention patents. In the future, BONTAC will adhere to the innovation-driven concept, continue to increase investment in research and development, dig into the field of synthetic biology, and commit to developing more high-quality raw material products. At the same time, BONTAC will actively expand the international market, and work with global partners to promote the prosperous development of synthetic biology industry. In this era full of challenges and opportunities, BONTAC is confident to make greater contributions to the cause of human health.
Introduction In the presence of oxygen, tumors produce adenosine triphosphate (ATP) through glycolysis instead of mitochondrial oxidative phosphorylation, a phenomenon known as the “Warburg effect”. Aerobic glycolysis caused by an altered tumor microenvironment is an important factor contributing to malignant tumor progression. Ginsenoside Rh2 (Rh2) can specifically reverse the shift from tumor aerobic glycolysis to oxidative phosphorylation to modulate the metabolic behavior of non-small cell lung cancer (NSCLC), ultimately promoting the “benignization” of NSCLC. The suppressive impacts of Rh2 on the malignant progression of NSCLC Rh2 inhibits the proliferation, invasion and migration, while promoting the apoptosis of NSCLC cells. Meanwhile, Rh2 treatment represses tumor lymph angiogenesis, as manifested by the obviously reduced expression of CD31. Moreover, Rh2 hinders the metastasis of NSCLC by inhibiting the epithelial mesenchymal transition (EMT), as evidenced by the upregulation of E-cadherin and downregulation of N-cadherin in lung tissues post Rh2 treatment. Underlying targets and mechanisms of Rh2 against NSCLC Rh2 hampers NSCLC aerobic glycolytic capacity, including glucose uptake and lactate production, through the HIF1-α/PDK4 pathway. Specifically, Rh2 targets hypoxia-inducible factor HIF-1α to downregulate its expression, subsequently reducing the expression of PDK4, a pivotal enzyme during the glucose oxidation process. By this way, Rh2 further suppresses aerobic glycolysis, promotes mitochondrial aerobic oxidative process, and stimulates the production of reactive oxygen species (ROS), thereby promoting tumor cells to enter the normal apoptotic program. The efficacy of Rh2 combined with DCA in NSCLC Sodium dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase (PDKs), has been commonly used in clinical practice as an anticancer drug targeting glycolysis, yet it has hepatotoxicity and neurotoxicity at high doses. Notably, the combination of Rh2 with DCA dramatically reverses the biometabolic behaviors of tumors, and further reduces the dosage of DCA, which decreases the toxicity of DCA, greatly increasing the drug efficacy. Conclusion Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in NSCLCs. It activates the apoptotic program of NSCLCs and exerts a potentiating and toxicity-reducing effect when used in combination with chemotherapeutic agents DCA, hinting its potential as an adjuvant against tumors. Reference Liu X, Li J, Huang Q, et al. Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in non-small cell lung cancer. Mol Med. 2024;30(1):56. Published 2024 Apr 26. doi:10.1186/s10020-024-00813-y BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.
Introduction Natural products, including single components or extracts of herbal medicines, have the features of good efficacy and low toxicity when used in tumor treatment. They have unique advantages in treating diseases compared with chemotherapeutic drugs due to their multi-component and multi-target effects. Strikingly, ginsenoside Rg3-loaded PLGA nanoparticles (Rg3-PLGA) coated with the membrane of tumor cell-derived microvesicles (Rg3-PLGA@TMVs), which is a nanoformulation of the natural product ginsenoside Rg3, have a significant role in the treatment of breast cancer when combined with the chemotherapeutic drug doxorubicin (DOX). Pharmacological roles of ginseng Rg3 in traditional Chinese medicine Ginseng Rg3, a tetracyclic triterpenoid saponin, is one of the main active component of ginseng. Ginseng has been regarded as one of the most valuable medicinal plants in Chinese traditional medicine for thousands of years, which is known as "the king of all tonic”. This perennial herb possesses the multiple pharmaceutical functions such as tonifying the vital energy, restoring the pulse and stabilizing the loss of vitality, invigorating spleen and benefiting lung, generating saliva or body fluid to quench thirst, as well as tranquilizing the mind and promoting the intelligence. The construction of Rg3-PLGA@TMVs Ginsenoside Rg3 is first encapsulated into PLGA nanoparticles using the nanoprecipitation method, followed by the extrusion-based coating of the TMV membrane onto Rg3-PLGA. This strategy combines the therapeutic properties of Rg3 with the precise delivery and sustained release capabilities of PLGA nanoparticles, further enhanced by the homologous targeting properties of TMVs. Anti-tumor effect and bio-safety of Rg3-PLGA@TMVs in 4T1 breast cancer Rg3-PLGA@TMVs induce robust anti-tumor immunity, recover the body weight loss caused by DOX in 4T1 breast cancer and overtly improve the anti-tumor effect of DOX, showing good stability and drug loading capability. These anti-tumor effects are chiefly realized by reducing phagocytic activity and acid phosphatase (ACP) levels, promoting the maturation of bone marrow-derived dendritic cells in vitro, and elevating the population of cytotoxic T lymphocytes (CD3+CD8+) and helper T cells (CD3+CD4+) in vivo. Importantly, this nanoformulation has minimal side effects and favorable biocompatibility, which can relieve the organ toxicity caused by DOX, especially the cardiac side effects. The administration of DOX and Rg3-PLGA@TMVs does not result in statistically significant changes in white blood cell (WBC) count and renal functional indicators, such as CREA and urea, nor in hepatic functional indicators, including AST and ALT. Conclusion Rg3-PLGA@TMVs achieve the co-delivery of antigens and adjuvants, which not only potentiate the anti-tumor effects, but also significantly alleviate the systemic toxicity caused by chemotherapeutic drugs, improving the overall health status of patients undergoing chemotherapy. Reference [1] Liu XR, Zhang KF, Li X, et al. Research progress on antitumor nanoscale drug delivery system of ginsenoside Rg3 [J]. Chin Trad Herb Drugs. 2023,54(22):7577-7587. DOI: 10.7501/j.issn.0253-2670.2023.22.034 [2]Zhang S, Zheng B, Wei Y, et al. Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviate toxicity [J]. Biomater Sci. Published online April 10, 2024. DOI:10.1039/d4bm00159a BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.